Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation

Clinical Cancer Research

Volumn 17, Issue 1, 2011, Pages 77-88

  Tawara, Isao ^a   Koyama, Motoko ^b   Liu, Chen ^c   Toubai, Tomomi ^a   Thomas, Dafydd ^a,d   Evers, Rebecca ^a   Chockley, Peter ^a   Nieves, Evelyn ^a   Sun, Yaping ^a   Lowler, Kathleen P ^a   Malter, Chelsea ^a   Nishimoto, Norihiro ^e   Hill, Geoffrey R ^b   Reddy, Pavan ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; MR 16 1; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; DONOR; DRUG EFFECT; EFFECTOR CELL; FEMALE; GRAFT DYSFUNCTION; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RHEUMATOID ARTHRITIS; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; INTERLEUKIN-6; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; TRANSPLANTATION, HOMOLOGOUS;

EID: 78751469023     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1198     Document Type: Article

References (52)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-9.
2. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol 2006;90:133-73.
3. Bleakley M, Riddell SR. Molecules and mechanisms of the graftversus-leukaemia effect. Nat Rev Cancer 2004;4:371-80.
4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
5. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graftversus-host disease: recent advances. Transl Res 2007;150:197-214.
6. Morris ES, Hill GR. Advances in the understanding of acute graftversus-host disease. Br J Haematol 2007;137:3-19.
7. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant ; 45:1-11.
8. Korngold R, Marini JC, De Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft- versus-leukemia responses. Biol Blood Marrow Transpl 2003;9:292-303.
9. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-26.
10. Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008;105:9041-6.
11. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
12. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
13. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32.
14. Thompson CA. FDA approves tocilizumab to treat rheumatoid arthritis. Am J Health Syst Pharm 2010;67:254.
15. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001;98:1594-600.
16. Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graftversus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992;54:457-62.
17. Givon T, Revel M, Slavin S. Potential use of inteleukin-6 in bone marrow tranpslantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. Blood 1994;83:1690-7.
18. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. Blood 2009;114:891-900.
19. Imamura M, Han M, Hashino S, et al. Effects of interleukin-6 on hematopoiesis in allogeneic and syngeneic bone marrow chimeras. Immunobiology 1994;191:21-37.
20. Givon T, Revel M, Slavin S. Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. Blood 1994;83:1690-7.
21. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007;25:139-70.
22. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36.
23. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-51.
24. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004;101:3921-6.
25. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005;11:1244-9.
26. Takagi N, Mihara M, Moriya Y, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998;41:2117-21.
27. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008;118:2562-73.
28. Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999;104:317-25.
29. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001;194:1433-40.
30. Toubai T, Malter C, Tawara I, et al. Immunization with host-type CD8α +dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood 2010;115:724-35.
31. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006;108:2485-92.
32. Grossmann J, Maxson JM, Whitacre CM, et al. New isolation technique to study apoptosis in human intestinal epithelial cells. Am J Pathol 1998;153:53-62.
33. Schwaighofer H, Herold M, Schwarz T, et al. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994;58:430-6.
34. Schwaighofer H, Kernan NA, O'Reilly RJ, et al. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution. Transplantation 1996;62:947-53.
35. Pechumer H, Leinisch E, Bender-Götze C, Ziegler-Heitbrock HW. Recovery of monocytes after bone marrow transplantation-rapid reappearance of tumor necrosis factor alpha and interleukin 6 production. Transplantation 1991;52:698-704.
36. Korngold R, Sprent J. Features of T cells causing H-2 restricted lethal graft-vs-host disease across minor histocompatibility barriers. J Exp Med 1982;155:872.
37. Tajima M, Wakita D, Noguchi D, et al. IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med 2008;205:1019-27.
38. Doganci A, Eigenbrod T, Krug N, et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005;115:313-25.
39. Nguyen VH, Zeiser R, Negrin RS. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transpl 2006;12:995-1009.
40. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001;193:1311-8.
41. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
42. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-5.
43. Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 transsignaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010;184:1543-51.
44. Mudter J, Amoussina L, Schenk M, et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cellderived IL-6. J Clin Invest 2008;118:2415-26.
45. Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV. IL-6 induces NF-kappa B activation in the intestinal epithelia. J Immunol 2003;171:3194-201.
46. Rockman SP, Demmler K, Roczo N, et al. Expression of interleukin-6, leukemia inhibitory factor and their receptors by colonic epithelium and pericryptal fibroblasts. J Gastroenterol Hepatol 2001;16:991-1000.
47. Kishimoto T. Interleukin-6 and its receptor in autoimmunity. J Autoimmun 1992;5Suppl A:123-32.
48. Reddy P, Negrin R, Hill GR. Mouse models of bone marrow transplantation. Biol Blood Marrow Transpl 2008;14:129-35.
49. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
50. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
51. Masui T, Hosotani R, Doi R, et al. Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction. Anticancer Res 2002;22:4093-100.
52. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.